Short- and long-term efficacy and safety of risperidone in adults with disruptive behavior disorders

摘要: Function in society can be severely affected by disruptive behaviors adults. To examine the efficacy and safety of risperidone treatment behavior disorders intellectually disabled Intellectually patients with disorder were randomly assigned to receive (n=39) a flexible dosage ranging from 1 4 mg/day (mean dosage, 1.45±0.08 mg/day) or placebo (n=38) for weeks double-blind treatment. Efficacy at endpoint was measured primarily using Aberrant Behavior Checklist (ABC); secondary measures included Problems Inventory Clinical Global Impressions scales. After this 4-week period, could enter open-label 48 weeks. Risperidone well tolerated, treated demonstrated significantly greater improvement on ABC than those who received [−27.3 points (52.8% improvement) versus −14.9 (31.3% improvement); P=0.036] also improved ratings. Over 48-week, follow-up there further decrease 6.3 (P≤0.05) initially 11.3 switched risperidone. These results achieved mean modal 1.8 mg/day. is efficacious tolerated managing adults intellectual disability.